Serguei Kozlov

Biochemistry, Genetics and Molecular Biology · Life Sciences

24h-index5.2kcitations67works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

RNA Research and Splicing(13), Nuclear Structure and Function(13), Cancer Research and Treatments(13), Genomics and Chromatin Dynamics(8), Pancreatic and Hepatic Oncology Research(7)

Publications67 total

High-grade serous ovarian cancer induced in different sites of origin in mice exemplifies diverse features of the human disease
iScience·2025Open Access
A novel retinoic acid receptor-γ agonist antagonizes immune checkpoint resistance in lung cancers by altering the tumor immune microenvironment
Scientific Reports·2023· 2 citedOpen Access
Abstract 1836: Combining a novel retinoic acid receptor-γ agonist with immune checkpoint blockade represses lung cancer growth <i>in vivo</i>
Cancer Research·2023
Supplementary Figure 2 from Novel Humanized Mesothelin-Expressing Genetically Engineered Mouse Models Underscore Challenges in Delivery of Complex Therapeutics to Pancreatic Cancers
2023Open Access
Supplementary Figure Legends from Novel Humanized Mesothelin-Expressing Genetically Engineered Mouse Models Underscore Challenges in Delivery of Complex Therapeutics to Pancreatic Cancers
2023Open Access
Supplementary Figure Legends from Novel Humanized Mesothelin-Expressing Genetically Engineered Mouse Models Underscore Challenges in Delivery of Complex Therapeutics to Pancreatic Cancers
2023Open Access
Data from Novel Humanized Mesothelin-Expressing Genetically Engineered Mouse Models Underscore Challenges in Delivery of Complex Therapeutics to Pancreatic Cancers
2023Open Access
Supplementary Figure 1 from Novel Humanized Mesothelin-Expressing Genetically Engineered Mouse Models Underscore Challenges in Delivery of Complex Therapeutics to Pancreatic Cancers
2023Open Access
Supplementary Figure 3 from Novel Humanized Mesothelin-Expressing Genetically Engineered Mouse Models Underscore Challenges in Delivery of Complex Therapeutics to Pancreatic Cancers
2023Open Access
Data from Novel Humanized Mesothelin-Expressing Genetically Engineered Mouse Models Underscore Challenges in Delivery of Complex Therapeutics to Pancreatic Cancers
2023Open Access
Supplementary Figure 2 from Novel Humanized Mesothelin-Expressing Genetically Engineered Mouse Models Underscore Challenges in Delivery of Complex Therapeutics to Pancreatic Cancers
2023Open Access
Supplementary Figure 1 from Novel Humanized Mesothelin-Expressing Genetically Engineered Mouse Models Underscore Challenges in Delivery of Complex Therapeutics to Pancreatic Cancers
2023Open Access
Supplementary Figure 3 from Novel Humanized Mesothelin-Expressing Genetically Engineered Mouse Models Underscore Challenges in Delivery of Complex Therapeutics to Pancreatic Cancers
2023Open Access
Supplementary Figure S8 from Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers
2023Open Access
Supplementary Figure S7 from Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers
2023Open Access
Supplementary Figure S7 from Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers
2023Open Access
Supplementary Figure S8 from Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers
2023Open Access
Supplementary Figure 4 from Temporal Molecular and Biological Assessment of an Erlotinib-Resistant Lung Adenocarcinoma Model Reveals Markers of Tumor Progression and Treatment Response
2023Open Access
Supplementary Figure 4 from Temporal Molecular and Biological Assessment of an Erlotinib-Resistant Lung Adenocarcinoma Model Reveals Markers of Tumor Progression and Treatment Response
2023Open Access
Abstract C058: Remodeling the tumor microenvironment by targeting integrin alpha V beta 3 (αvβ3) expressing cells in pancreatic cancer
Cancer Research·2022
page 1 of 4Next →

Frequent Co-authors

Colin L. Stewart(14), Theresa M. Guerin(13), P. Sonderegger(9), Nathan Pate(7), Laura Bassel(7), Christine Alewine(6), Udo Rudloff(5), Brendan Hagerty(5), T. Norene O’Sullivan(5), N. Keith Collins(5), Wendi Custer Lawrence(5), Jian Xu(5), Zachary Knotts(4), Lídia Hernandez(4), Paolo Cinelli(4), Beat Kunz(4), Jerome Schlomer(4), Xianyu Zhang(4), Jan Lammerding(3), P. Christian Schulze(3)